MedicalPersonalized MedicineProduct Launch

FabRx launches M3DIMAKER 3D printer for personalized medicine

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

FabRx Ltd., a biotech spin-out from University College London (UCL) in the UK, has announced the availability of its M3DIMAKER system, the first pharmaceutical 3D printer developed for the production of customized medicine. The system was first unveiled in Switzerland in September 2019 at the ILMAC Exhibition and now, after extensive testing, it is ready for the market.

The newly launched pharmaceutical 3D printer is designed to produce personalized 3D printed tablets called Printlets. The hardware can print pills with a precise dose of medication as well as print “polypills” with several medications integrated into a single tablet. The ability to combine drugs into a single pill could make it easier for patients with complicated medication regimens to manage their prescriptions.

The M3DIMAKER 3D printer is controlled by a specialized software platform that enables users to select the dose prescribed by the pharmacist and clinician. The software also integrates fingerprint access control and a data matrix reader which ensure reliability and security. In other words, only qualified personnel have access to many of the technology’s features. The pharmaceutical 3D printer is also equipped with advanced in-line quality control procedures, including camera monitoring for defect detection.

FabRX M3DIMAKER 3D printer

The system is also adaptable: customers can choose between three different print nozzles depending on their specific applications, whether they are printing small batches of pills for pre-clinical and clinical studies, or printing personalized tablets for clinical practice. According to FabRx, the M3DIMAKER can produce one-month’s worth of medication (28 Printlets) in roughly eight minutes, depending on the type of drug being printed.

“We are delighted to be launching our state-of-the-art 3D printing system in light of the recommendations from the regulatory organisations into the pharmaceutical market,” commented Dr. Alvaro Goyanes, Director of Development at FabRx. “I truly believe that we are one step closer to personalised medicine thanks to the M3DIMAKER.”

Personalized medicine is a new frontier in the healthcare and pharmaceutical sectors. Today, most drugs are created using mass manufacturing methods, which create standardized dosage forms. In some cases, this can lead to inappropriate dosing. In pediatrics, for instance, it is not uncommon for medication to be split or crushed to achieve the right dosage, which is imprecise and can lead to dosing errors. Tablets with personalized dosage could offer a safe alternative to these more do-it-yourself approaches.

Research 2021
Ceramic AM Market Opportunities and Trends

This market study from 3dpbm Research provides an in-depth analysis and forecast of the ceramic additive ma...

Tess Boissonneault

Tess Boissonneault is a Montreal-based content writer and editor with five years of experience covering the additive manufacturing world. She has a particular interest in amplifying the voices of women working within the industry and is an avid follower of the ever-evolving AM sector. Tess holds a master's degree in Media Studies from the University of Amsterdam.

Related Articles

Back to top button

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services

STAY AHEAD

OF THE CURVE

Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*

WELCOME ON BOARD!